Group 1 - The core viewpoint indicates that the Chinese pharmaceutical sector, particularly the innovative drug segment, is poised for a rebound in the second half of the year, with significant growth in the approval of innovative drugs and medical devices [1][2] - As of July 4, the Hong Kong pharmaceutical ETF has seen a net value increase of 71.46% over the past year, reflecting strong market performance [1] - In the first half of the year, China approved 43 innovative drugs and 45 innovative medical devices, marking year-on-year growth of 59% and 87% respectively, showcasing the positive impact of reform policies on industry development [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index consists of 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.44% of the index [4] - The top ten weighted stocks in the CSI Hong Kong Stock Connect Healthcare Index include companies like Innovent Biologics and WuXi Biologics, with varying performance in terms of stock price changes [6] - The CSI Medical and Medical Device Innovation Index includes 30 companies with strong profitability and growth potential, with the top ten stocks representing 63.62% of the index [7] Group 3 - The latest scale of the Medical Innovation ETF has reached 1.478 billion yuan, indicating a growing interest in the sector [2] - The performance of individual stocks within the Medical Innovation ETF shows mixed results, with some stocks like TianTan Bio leading gains while others like Sangfor Technologies are experiencing declines [9] - The index aims to reflect the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [7]

Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the **pharmaceutical industry**, focusing on **innovative drugs** and **biotechnology** advancements, particularly in the context of **PD-1 plus assets** and related companies. Core Insights and Arguments 1. **Performance of PD-1 plus Assets**: PD-1 plus assets have shown strong performance, particularly following the presentation of the Hamani two study results by 康方生物, which improved market confidence in EVOS monoclonal antibody and related companies [5][6] 2. **Strategic Collaborations**: Major pharmaceutical companies are accelerating their investments in PD-1 plus assets, with 三生制药 licensing PD-1 v j dual antibody rights to Pfizer for an upfront payment of **$1.25 billion** and 百安泰克 partnering with BMS for PDL one V E G F dual antibody development [6][7] 3. **Emerging Hotspots for Innovative Drugs**: Key areas of interest for the second half of the year include: - **Dual antibodies in autoimmune diseases** (e.g., TSLP dual antibody) - **Protein degradation agents** (Protac) - **Next-generation TCE dual antibodies** in solid tumors - **ADC iterative development** [9] 4. **HER3 ADC Development**: HER3 ADC has entered phase three trials, showing potential as a leading target combination. Initial preclinical data from 信达生物 on EGFR and B7H3 ADCs indicate significant potential for overcoming resistance issues [10] 5. **Nuclear Medicine Advances**: 诺华's Provelto has expanded its indications, with domestic companies like 科伦博泰 and 百利天恒 also involved in this field [11] 6. **Cardiovascular RNA Therapies**:礼来’s small interfering RNA therapy for lipoprotein a has shown positive results in phase two trials, indicating potential for domestic companies like 悦康药业 and 成都先导 to benefit from these advancements [12] 7. **CAR-T Therapy Developments**: The acquisition of 百泰 by 艾伯维 for its in vivo CAR-T technology highlights the growing interest in this area, with potential benefits for domestic companies like 科济药业 [13][14] Additional Important Insights 1. **Investment Opportunities**: The pharmaceutical industry is expected to see continued investment opportunities in innovative drugs and supply chain upstream sectors, with a focus on companies showing high growth in their mid-year reports [2] 2. **Emerging Technologies**: Notable technologies to watch include brain-computer interfaces, AI in medicine, and rehabilitation robotics, alongside the development of universal CAR-T therapies [3] 3. **Generic Drug Sector Performance**: The generic drug index has outperformed the pharmaceutical index, indicating a potential for revaluation among leading generic companies [15] 4. **Market Dynamics**: The conference highlighted the importance of monitoring market dynamics, including the impact of policy changes and the performance of various sectors within the pharmaceutical industry [4][28] This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future outlook of the pharmaceutical industry, particularly in relation to innovative drug development and strategic collaborations.

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry [1] Core Insights - The value of innovative drugs going overseas is continuously validated, with an upward trend in valuations expected to persist. The collaboration between Chinese biotech firms and multinational corporations (MNCs) is increasing, particularly in the area of PD-1 and VEGF dual antibodies [2][3] - The recent approval of Vuxin Qibai monoclonal antibody marks the beginning of a new era in biological treatment for gout, highlighting the significant market potential for gout treatments in China and globally [4] - The trend towards more effective and scientific weight loss solutions is emerging, with new clinical data and partnerships in the GLP-1 and other related drug classes [5] - The focus on autoimmune diseases is growing, with significant breakthroughs in drug development and international collaborations [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index increased by 3.64% in the week from June 28 to July 4, 2025, outperforming the CSI 300 index by 2.10 percentage points, ranking 4th among 31 primary industry indices [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) is 35.12, above the historical five-year average of 32.30 [46] 3. Recent Research Achievements - The report highlights various recent research outputs from the Huaxin pharmaceutical team, including deep reports on the growth trends in blood products and inhalation preparations [52] 4. Recent Industry Policies and News - A recent policy from the National Healthcare Security Administration supports the high-quality development of innovative drugs, emphasizing increased support for R&D and clinical applications [54] - Notable news includes the approval of new drug applications and significant clinical trial advancements by various companies, indicating a vibrant pipeline in the pharmaceutical sector [55][56]

创新药行情持续火热，建议关注 PD-1/L1 双抗及多抗 [Table_Industry] 医药生物行业周报 [Table_ReportTime] 2025 年 7 月 6 日 证券研究报告 行业研究 [Table_ReportType] 行业周报 医药生物 医药生物 投资评级 看好 上次评级 看好 [Table_A 唐爱金 uthor 医药首席分析师 ] 执业编号：S1500523080002 邮 箱：tangaijin@cindasc.com 贺鑫 医药行业分析师 执业编号：S1500524120003 邮 箱：hexin1@cindasc.com 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com 章钟涛 医药行业分析师 执业编号：S1500524030003 邮 箱：zhangzhongtao@cindasc.com 赵丹 医药行业分析师 执业编号：S1500524120002 邮 箱：zhaodan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [9]. Core Insights - The pharmaceutical index increased by 3.64% during the week of June 30 to July 4, outperforming both the ChiNext and CSI 300 indices, indicating a positive market sentiment towards innovative drugs and brain-computer interface technologies [14][15]. - The report emphasizes the strong performance of PD-1 Plus drugs, which are seen as a driving force in the current market recovery, supported by significant business development (BD) deals and a favorable industry trend [2][15]. - The outlook for 2025 remains optimistic, focusing on innovative drugs, new technologies, and the restructuring of supply chains [3][16]. Summary by Sections 1. Industry Overview - The pharmaceutical sector is experiencing a rebound, with innovative drugs and brain-computer interfaces leading the charge. The report highlights the importance of PD-1 Plus drugs in this recovery [14][15]. 2. Innovative Drug Selection - PD-1 Plus drugs are gaining traction, with significant overseas collaborations and clinical trial advancements. The report notes that companies like Innovent Biologics and BeiGene are at the forefront of this trend [20][21]. - The report suggests focusing on companies with promising PD-1/IL-2 combinations and those that have successfully entered international markets [23]. 3. Investment Strategies - The report outlines a strategy focusing on core stocks in the innovative drug space, particularly those with strong growth potential and upcoming clinical data releases [3][17]. - Key companies to watch include Innovent Biologics, Zai Lab, and others involved in PD-1 Plus and related technologies [4][17]. 4. Market Performance - The report provides a comparative analysis of the performance of various indices, noting that the innovative drug index has outperformed the broader pharmaceutical index and the CSI 300 index since the beginning of 2025 [41][42]. - The report also highlights the performance of specific stocks within the innovative drug sector, indicating a positive trend for companies like Zai Lab and BeiGene [45]. 5. Future Outlook - The report anticipates continued optimism in the pharmaceutical sector, particularly around innovative drugs and new technologies such as AI in healthcare and rehabilitation robotics [3][16]. - The focus will be on identifying high-growth opportunities in the innovative drug space and leveraging the ongoing restructuring of supply chains [3][19].

Investment Rating - The report rates the pharmaceutical industry as "Overweight," indicating a positive outlook for the sector compared to the overall market performance [4][27]. Core Insights - The pharmaceutical sector saw a weekly increase of 3.6%, outperforming the Shanghai Composite Index, which rose by 1.4% [4][5]. - The report highlights the introduction of supportive policies for innovative drugs and high-end medical devices, including a comprehensive support system for innovative drug development, access, usage, and payment [4][12]. - The negotiation for the 2025 National Medical Insurance Drug List has officially started, with plans to include innovative drugs in commercial health insurance for the first time [4][13]. - AstraZeneca and Summit are reportedly negotiating a deal worth over $15 billion for the drug AK112, indicating significant activity in the innovative drug market [4][16]. - The report emphasizes the growth in revenue and licensing deals for innovative drugs, suggesting a trend towards broader market expansion [4]. Market Performance - The pharmaceutical sector's overall valuation stands at 29.8 times PE (2025E), ranking 6th among 31 primary industries [4][11]. - The performance of various sub-sectors includes: - Raw materials (+5.8%) - Chemical preparations (+4.9%) - Other biological products (+8.3%) - Medical devices (-0.2%) [4][7]. Key Events - On July 1, the National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, outlining 16 specific initiatives [4][12]. - The National Medical Products Administration announced measures to support the innovation of high-end medical devices, focusing on key areas such as medical robots and AI medical devices [4][13]. - Longcheng Gaoxin announced plans to issue H shares and list on the Hong Kong Stock Exchange, enhancing its international brand image [4][15].

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology industry [1] Core Insights - The PD1/VEGF dual antibody is leading the next generation of immuno-oncology (IO) treatments, with significant attention on companies like Kangfang Biopharma and Shenzhou Cell [5][6] - The report highlights the approval of the first domestic recombinant human coagulation factor VIIa by Zhengda Tianqing, marking a significant milestone in the industry [2] - The report suggests a ranking of favored sub-industries: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [3][12] Summary by Sections Industry Performance - The A-share pharmaceutical index has increased by 3.9% this week and 10% year-to-date, outperforming the CSI 300 by 3.0% and 8.9% respectively [6][11] - The H-share biotechnology index has seen a rise of 5.0% this week and 62% year-to-date, outperforming the Hang Seng Technology Index by 7.3% and 44% respectively [6][11] R&D Progress and Company Dynamics - The report details the significant advancements in innovative drugs, including the initiation of Phase III clinical trials for HER2 dual antibodies by Zhengda Tianqing [2] - It emphasizes the competitive edge of PD1/VEGF dual antibodies, particularly the success of Kangfang Biopharma's Ivosidenib in clinical trials against the leading PD-1 inhibitor, Pembrolizumab [17][23] Market Insights - The report notes that the pharmaceutical sector has shown strong performance, particularly in innovative drugs, with significant gains in stock prices for companies like Saily Medical (+55%) and Shenzhou Cell (+47%) [6][11] - The report also highlights the performance of various sub-sectors, with chemical drugs and biological products showing substantial price increases [6][11] Specific Company Recommendations - The report recommends focusing on companies such as Shenzhou Cell, Huahai Pharmaceutical, and Rongchang Biopharma from the perspective of PD1/VEGF dual antibodies [3][12] - It also suggests looking at companies with strong growth potential like Borui Pharmaceutical and Innovent Biologics, as well as those with low valuations such as Zhaoli Pharmaceutical and Dong'e Ejiao [3][12]

Group 1 - The core viewpoint of the news is that the innovative drug sector in the Hong Kong stock market is experiencing a significant surge, with several companies seeing substantial stock price increases, particularly Huahao Zhongtian Pharmaceutical, which saw its stock price double in just three trading days [1][2][3] - Huahao Zhongtian Pharmaceutical has emerged as a standout performer, with a stock price increase of 55% on July 3 and a total increase of 95% by July 4, driven by its focus on developing innovative cancer drugs [2][3] - Other notable companies in the innovative drug sector include Rongchang Biopharmaceutical, which rose approximately 15% after licensing global development rights for a drug for $4.23 billion, and Basestone Pharmaceuticals, which saw a stock price increase of over 13% after disclosing new drug candidates [3][6] Group 2 - The first half of 2025 is expected to witness a wave of new listings in the Hong Kong biopharmaceutical market, with 10 companies successfully listing, most of which are innovative drug firms [4][5] - Newly listed innovative drug companies have shown impressive performance, with Yingen Biopharmaceutical's stock price soaring by 193.23% since its April 15 listing, and Yaojie Ankang's stock price increasing by 158.17% since its June 23 listing [5] - Analysts are optimistic about the future of the innovative drug sector, citing supportive policies and improvements in the sector's fundamentals as key factors driving the current market momentum [6][7]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7]. Core Insights - The National Healthcare Security Administration has initiated the adjustment work for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which is expected to include multiple new drugs for negotiation [2]. - From July 1, 2024, to June 30, 2025, approximately 19 oncology drugs and 23 non-oncology drugs are anticipated to be approved and may participate in the 2025 medical insurance negotiations [2]. Summary by Sections 1. Weekly New Drug Market Review - From June 30, 2025, to July 4, 2025, the top five companies in the new drug sector by stock price increase were: - Zai Lab (45.00%) - Sanofi (36.30%) - Frontier Biopharma (30.60%) - Micron Biomedicine (30.50%) - Kangfang Biopharma (25.50%) - The top five companies with the largest declines were: - Oconview (-12.90%) - Kexin Pharmaceuticals (-9.10%) - Dongyao Pharmaceuticals (-6.70%) - Lepu Biopharma (-6.40%) - Yifang Biopharma (-3.60%) [1][16]. 2. Weekly New Drug Industry Analysis - The adjustment work for the 2025 medical insurance catalog has begun, allowing new generic drugs approved between January 1, 2020, and June 30, 2025, to apply for inclusion [2]. - The expected new drugs for negotiation in 2025 will primarily be those approved between July 1, 2024, and June 30, 2025 [2]. 3. Weekly New Drug Approval & Acceptance Status - This week, 22 new drugs or new indications received approval for market entry, while one new drug application was accepted [3][26]. 4. Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 46 new drug clinical applications were approved this week, and 31 new drug clinical applications were accepted [4][32]. 5. Key Domestic Market Events - Key events included the approval of a MET inhibitor by Hutchison China MediTech for treating advanced non-squamous non-small cell lung cancer and the approval of an anti-IL-1β monoclonal antibody by Junshi Biosciences for treating acute attacks of gouty arthritis [5][12]. 6. Key Overseas Market Events - Notable overseas events included Moderna's positive progress in its seasonal flu mRNA vaccine study, Regeneron's accelerated approval of a dual antibody for multiple myeloma, and Pfizer's announcement of a significant reduction in bleeding rates in hemophilia patients [13].

Investment Rating - The industry rating is "Outperform the Market" [7] Core Viewpoints - The report highlights the potential of subcutaneous immunoglobulin (SCIG) as the next major product in the blood products sector, with Tian Tan Biologics positioned to be the first domestic manufacturer to market this product [3][4][15] - The global market size for SCIG is projected to reach approximately $4.9 billion in 2024, which is about half the size of the intravenous immunoglobulin (IVIG) market [3][19][26] - The report emphasizes the advantages of SCIG over IVIG, including better tolerability, lower incidence of adverse reactions, lower economic costs, higher patient satisfaction, and ease of self-administration [3][19][21] Summary by Sections Market Review - The CITIC Pharmaceutical Index increased by 3.6% during the week of June 30 to July 4, 2025, outperforming the CSI 300 Index by 2.0 percentage points [3][36] - Year-to-date, the CITIC Pharmaceutical Index has risen by 10.8%, surpassing the CSI 300 Index by 9.6 percentage points [3][36] - Notable stock performances included Seer Medical (+51.55%), Guangsheng Tang (+48.64%), and Shenzhou Cell (+45.01%) [3][51] Focus on SCIG - SCIG is recognized as the third-largest segment in the global blood products market, with a projected size of $4.9 billion, representing 15.5% of the market [26][29] - The report forecasts a compound annual growth rate (CAGR) of 7.2% for the immunoglobulin market (IVIG + SCIG) from 2025 to 2034, with SCIG expected to be the fastest-growing segment [26][29] - Tian Tan Biologics is expected to gain a significant competitive advantage as it is on track to be the first company to launch SCIG in China, with its application for production submitted and under review [3][34] Investment Recommendations - The report suggests focusing on innovative drugs as a primary investment theme, with a recommendation to consider leading companies and those with potential catalysts in their development pipelines [4][5] - The recommended investment portfolio includes companies such as Kangfang Biologics, Xinda Biologics, and Tian Tan Biologics [4][5][12]